BioSpace News Archive

Today, the Bladder Cancer Advocacy Network (BCAN) announced the launch of a new, free call center resource for bladder cancer patients and loved ones.

Rejuve.AI and TruDiagnostic have partnered to generate insights into the biology of aging and the relationship between DNA methylation (measuring DNA expression regulatory elements), metabolomics (the study of chemical metabolites of body processes), and proteomics (the study peptides and proteins) using TruDiagnostic’s rich data set and Rejuve’s AI expertise.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site.

Ocean Biomedical, a next-generation biopharma company, and Aesther Healthcare Acquisition Corp., a publicly traded special purpose acquisition company, shared an update on key company activities.

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimer’s disease dementia.

Sanford Burnham Prebys announced plans to recruit up to 20 new faculty positions in research areas including cancer, neurodegeneration and computational biology.

Bayer today announced that Ben Kampelman, formerly Director, Strategic Communications for Crop Science North America, has been appointed to the role of Vice President of Communications, Crop Science North America.

Decibel Therapeutics today announced authorization of its Clinical Trial Application (CTA) by the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate.

Prelude Corporation, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced it has entered into a managed care provider agreement with Medical Cost Containment Professionals LLC to process out-of-network claims for PreludeDx’s DCISionRT® test.

Biomica Ltd. today announced its CEO and VP R&D will both be participating in 7th Annual Microbiome Movement Drug Development Europe, taking place in London, UK, between January 31 and February 2, 2023.